Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease

Fig. 2

Time to progression. Time to progression in months for patients achieving stable disease (SD) and objective response (OR) treated with (a): streptozotocin/5-FU, (b): everolimus and (c) and (d): PRRT. Radiological response evaluation is done with the “conventional method” in (a), (b) and (c), where any unequivocal change in the the size of known tumors are considered significant. In (d) the response evaluation was done according to the RECIST 1.1 criteria

Back to article page